LATE MORTALITY AND LEVAMISOLE ADJUVANT THERAPY IN COLORECTAL

被引:16
作者
CHLEBOWSKI, RT
LILLINGTON, L
NYSTROM, JS
SAYRE, J
机构
[1] UNIV CALIF LOS ANGELES,HARBOR MED CTR,DEPT MED,DIV MED ONCOL,TORRANCE,CA 90509
[2] UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOSTAT,LOS ANGELES,CA
关键词
D O I
10.1038/bjc.1994.214
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Beginning in 1975, 78 patients with resected stage B and C colorectal carcinoma were randomly assigned (2:1) to receive either levamisole 2.5 mg kg(-1) day(-1) given for 2 days every week for 18 months or placebo therapy in the same schedule. Pretreatment characteristics (age, gender, disease site, CEA and stage) and the pattern of follow-up were similar in both groups. For the first 5 years following randomisation, relapse-free survival and overall survival were similar in the two treatment groups. Subsequently, excess late mortality was associated with levamisole group assignment. Consequently, overall survival was somewhat greater in the placebo group than in the levamisole group, 68% vs 38% (P < 0.08). For patients surviving 5 years from randomisation, subsequent survival favoured placebo over levamisole (100% vs 57%; P<0.03). The absolute numbers of deaths were 27 in the levamisole group (19 definitely cancer related) and seven in the group placebo (five definitely cancer related). This long-term result seen with a more intensive adjuvant levamisole dose and schedule suggests: (1) other levamisole adjuvant trials in patients with colorectal cancer should be examined for long-term outcome; (2) future trials utilising the even higher levamisole dosage required for clinical immunomodulation should proceed cautiously.
引用
收藏
页码:1094 / 1097
页数:4
相关论文
共 27 条
[1]   LEVAMISOLE AND SURGERY IN BRONCHIAL-CARCINOMA PATIENTS - INCREASE IN DEATHS FROM CARDIORESPIRATORY FAILURE [J].
ANTHONY, HM ;
MEARNS, AJ ;
MASON, MK ;
SCOTT, DG ;
MOGHISSI, K ;
DEVERALL, PB ;
ROZYCKI, ZJ ;
WATSON, DA .
THORAX, 1979, 34 (01) :4-12
[2]   ADJUVANT THERAPY OF POOR PROGNOSIS COLON CANCER WITH LEVAMISOLE - RESULTS OF AN EORTC DOUBLE-BLIND RANDOMIZED CLINICAL-TRIAL [J].
ARNAUD, JP ;
BUYSE, M ;
NORDLINGER, B ;
MARTIN, F ;
PECTOR, JC ;
ZEITOUN, P ;
ADLOFF, A ;
DUEZ, N .
BRITISH JOURNAL OF SURGERY, 1989, 76 (03) :284-289
[3]   ADJUVANT CHEMOTHERAPY AND IMMUNOTHERAPY FOR COLORECTAL-CANCER - PRELIMINARY COMMUNICATION [J].
BANCEWICZ, J ;
CALMAN, KC ;
MACPHERSON, SG ;
MCARDLE, CS ;
MCVIE, JG ;
SOUKOP, M .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1980, 73 (03) :197-199
[5]   LONG-TERM SURVIVAL FOLLOWING LEVAMISOLE OR PLACEBO ADJUVANT TREATMENT OF COLORECTAL-CANCER - A WESTERN CANCER STUDY-GROUP TRIAL [J].
CHLEBOWSKI, RT ;
NYSTROM, S ;
REYNOLDS, R ;
WEINER, JM ;
BATEMAN, JR .
ONCOLOGY, 1988, 45 (03) :141-143
[6]  
CHLEBOWSKI RT, 1982, P INT CANCER C, V13, P252
[7]   MULTIFOCAL INFLAMMATORY LEUKOENCEPHALOPATHY WITH 5-FLUOROURACIL AND LEVAMISOLE [J].
HOOK, CC ;
KIMMEL, DW ;
KVOLS, LK ;
SCHEITHAUER, BW ;
FORSYTH, PA ;
RUBIN, J ;
MOERTEL, CG ;
RODRIGUEZ, M .
ANNALS OF NEUROLOGY, 1992, 31 (03) :262-267
[8]   DOSE-RELATED IMMUNOLOGICAL EFFECTS OF LEVAMISOLE IN PATIENTS WITH CANCER [J].
JANIK, J ;
KOPP, WC ;
SMITH, JW ;
LONGO, DL ;
ALVORD, WG ;
SHARFMAN, WH ;
FENTON, RG ;
SZNOL, M ;
STEIS, RG ;
CREEKMORE, SP ;
EWEL, CH ;
HURSEY, J ;
URBA, WJ .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) :125-135
[9]   SURGICAL ADJUVANT THERAPY OF LARGE-BOWEL CARCINOMA - AN EVALUATION OF LEVAMISOLE AND THE COMBINATION OF LEVAMISOLE AND FLUOROURACIL [J].
LAURIE, JA ;
MOERTEL, CG ;
FLEMING, TR ;
WIEAND, HS ;
LEIGH, JE ;
RUBIN, J ;
MCCORMACK, GW ;
GERSTNER, JB ;
KROOK, JE ;
MALLIARD, J ;
TWITO, DI ;
MORTON, RF ;
TSCHETTER, LK ;
BARLOW, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (10) :1447-1456
[10]   LEVAMISOLE AND FLUOROURACIL FOR ADJUVANT THERAPY OF RESECTED COLON-CARCINOMA [J].
MOERTEL, CG ;
FLEMING, TR ;
MACDONALD, JS ;
HALLER, DG ;
LAURIE, JA ;
GOODMAN, PJ ;
UNGERLEIDER, JS ;
EMERSON, WA ;
TORMEY, DC ;
GLICK, JH ;
VEEDER, MH ;
MAILLIARD, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (06) :352-358